Aspire Private Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Aspire Private Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-275	Closed	-$213K	–	185
2026 Q1	$213K	Sell	275 -45	-14%	-$34.5K	0.05%	168
2025 Q4	$247K	Buy	+320	New	+$217K	0.06%	155
2024 Q4	–	Sell	-10	Closed	-$10.5K	–	522
2024 Q3	$10.5K	Hold	10	–	–	﹤0.01%	375
2024 Q2	$10.5K	Hold	10	–	–	﹤0.01%	380
2024 Q1	$9.63K	Hold	10	–	–	﹤0.01%	408
2023 Q4	$8.78K	Hold	10	–	–	﹤0.01%	409
2023 Q3	$8.23K	Hold	10	–	–	﹤0.01%	417
2023 Q2	$7.18K	Hold	10	–	–	﹤0.01%	412
2023 Q1	$8.22K	Hold	10	–	–	﹤0.01%	392
2022 Q4	$7.21K	Hold	10	–	–	﹤0.01%	390
2022 Q3	$7K	Hold	10	–	–	﹤0.01%	388
2022 Q2	$6K	Hold	10	–	–	﹤0.01%	386
2022 Q1	$7K	Hold	10	–	–	﹤0.01%	367
2021 Q4	$6K	Sell	10 -20	-67%	-$12.3K	﹤0.01%	397
2021 Q3	$18K	Buy	30 +10	+50%	+$6.21K	0.01%	275
2021 Q2	$11K	Buy	+20	New	+$10.1K	﹤0.01%	320
2021 Q1	–	Sell	-10	Closed	-$5K	–	597
2020 Q4	$5K	Sell	10 -72	-88%	-$38.9K	﹤0.01%	304
2020 Q3	$46K	Sell	82 -24	-23%	-$14.6K	0.02%	207
2020 Q2	$66K	Sell	106 -70	-40%	-$39.7K	0.03%	161
2020 Q1	$86K	Buy	176 +166	+1,660%	+$68.5K	0.05%	128
2019 Q4	$4K	Hold	10	–	–	﹤0.01%	322
2019 Q3	$3K	Hold	10	–	–	﹤0.01%	330
2019 Q2	$3K	Hold	10	–	–	﹤0.01%	368
2019 Q1	$4K	Hold	10	–	–	﹤0.01%	380
2018 Q4	$4K	Buy	+10	New	+$3.66K	﹤0.01%	365

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Aspire Private Capital's REGN Position: Q2 2026 in Review

Aspire Private Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 275 shares — an estimated $213K sold.

Aspire Private Capital first reported a position in REGN in Q4 2018 and held it in 25 quarters. The position peaked at $247K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Aspire Private Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Aspire Private Capital sold 275 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $213K.
Aspire Private Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 25 quarters.
Aspire Private Capital's Regeneron Pharmaceuticals position peaked at $247K in Q4 2025.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aspire Private Capital's 13F filing for Q2 2026, filed 15 Jul 2026.